Skip to main content
SpringerLink
Log in

Prevent aortic complications in patients with Marfan’s syndrome by targeting the underlying histological and haemodynamic abnormalities

  • Disease Management
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II

References

  1. Silverman DI, Burton KJ, Gray J, et al. Life expectancy in the Marfan syndrome. Am J Cardiol 1995 Jan 15; 75(2): 157–60

    Article  PubMed  CAS  Google Scholar 

  2. Yetman AT. Cardiovascular pharmacotherapy in patients with Marfan syndrome. Am J Cardiovasc Drugs 2007; 7(2): 117–26

    Article  PubMed  CAS  Google Scholar 

  3. Milewicz DM, Dietz HC, Miller DC. Treatment of aortic disease in patients with Marfan syndrome. Circulation 2005 Mar 22; 111(11): el50–7

    Article  Google Scholar 

  4. DePaepe A, Devereux RB, Dietz HC, et al. Revised diagnostic criteria for the Marfan syndrome. Am J Med Genet 1996 Apr 24; 62(4): 417–26

    Article  PubMed  Google Scholar 

  5. Pereira L, Andrikopoulos K, Tian J, et al. Targetting of the gene encoding fibrillin-1 recapitulates the vascular aspect of Marfan syndrome. Nat Genet 1997 Oct; 17(2): 218–22

    Article  PubMed  CAS  Google Scholar 

  6. Fedak PW, deSa MP, Verma S, et al. Vascular matrix remodeling in patients with bicuspid aortic valve malformations: implications for aortic dilatation. J Thorac Cardiovasc Surg 2003 Sep; 126(3): 797–806

    Article  PubMed  Google Scholar 

  7. Nataatmadja M, West M, West J, et al. Abnormal extracellular matrix protein transport associated with increased apoptosis of vascular smooth muscle cells in Marfan syndrome and bicuspid aortic valve thoracic aortic aneurysm. Circulation 2003 Sep 9; 108Suppl. 1: II329–34

    PubMed  Google Scholar 

  8. Touyz RM. Reactive oxygen species and angiotensin II signaling in vascular cells: implications in cardiovascular disease. Braz J Med Biol Res 2004 Aug; 37(8): 1263–73

    Article  PubMed  CAS  Google Scholar 

  9. Sachdev NH, DiGirolamo N, McCluskey PJ, et al. Lens dislocation in Marfan syndrome: potential role of matrix metalloproteinases in fibrillin degradation. Arch Ophthalmol 2002 Jun; 120(6): 833–5

    PubMed  Google Scholar 

  10. Jeremy RW, Huang H, Hwa J, et al. Relation between age, arterial distensibility, and aortic dilatation in the Marfan syndrome. Am J Cardiol 1994 Aug 15; 74(4): 369–73

    Article  PubMed  CAS  Google Scholar 

  11. Baumgartner D, Baumgartner C, Matyas G, et al. Diagnostic power of aortic elastic properties in young patients with Marfan syndrome. J Thorac Cardiovasc Surg 2005 Apr; 129(4): 730–9

    Article  PubMed  Google Scholar 

  12. Gott VL, Greene PS, Alejo DE, et al. Replacement of the aortic root in patients with Marfan’s syndrome. N Engl J Med 1999 Apr 29; 340(17): 1307–13

    Article  PubMed  CAS  Google Scholar 

  13. Shores J, Berger KR, Murphy EA. Progression of aortic dilatation and the benefit of long-term beta-adrenergic blockade in Marfan’s syndrome. N Engl J Med 1994 May 12; 330(19): 1335–41

    Article  PubMed  CAS  Google Scholar 

  14. Rossi-Foulkes R, Roman MJ, Rosen SE, et al. Phenotypic features and impact of beta blocker or calcium antagonist therapy on aortic lumen size in the Marfan syndrome. Am J Cardiol 1999 May 1; 83(9): 1364–8

    Article  PubMed  CAS  Google Scholar 

  15. Yetman AT, Bornemeier RA, McCrindle BW. Usefulness of enalapril versus propranolol or atenolol for prevention of aortic dilation in patients with the Marfan syndrome. Am J Cardiol 2005 May 1; 95(9): 1125–7

    Article  PubMed  CAS  Google Scholar 

  16. Selamet Tierney ES, Feingold B, Printz BF, et al. Beta-blocker therapy does not alter the rate of aortic root dilation in pediatric patients with Marfan syndrome. J Pediatr 2007 Jan; 150(1): 77–82

    Article  Google Scholar 

  17. Meijboom LJ, Drenthen W, Pieper PG, et al. Obstetric complications in Marfan syndrome. Int J Cardiol 2005 Oct 14; 110(1): 53–9

    Article  PubMed  Google Scholar 

  18. Elliott WJ. Clinical features in the management of selected hypertensive emergencies. Prog Cardiovasc Dis 2006 Mar–Apr; 48(5): 316–25

    Article  PubMed  Google Scholar 

  19. Lob H, Rosenkranz AC, Breitenbach T, et al. Antioxidant and nitric oxide-sparing actions of dihydropyridines and ACE inhibitors differ in human endothelial cells. Pharmacology 2006; 76(1): 8–18

    Article  PubMed  CAS  Google Scholar 

  20. Oshima T, Ozono R, Yano Y, et al. Beneficial effect of T-type calcium channel blockers on endothelial function in patients with essential hypertension. Hypertens Res 2005 Nov; 28(11): 889–94

    Article  PubMed  CAS  Google Scholar 

  21. Peng H, Carretero OA, Vuljaj N, et al. Angiotensin-converting enzyme inhibitors: a new mechanism of action. Circulation 2005 Oct 18; 112(16): 2436–45

    Article  PubMed  CAS  Google Scholar 

  22. Nagashima H, Sakomura Y, Aoka Y, et al. Angiotensin II type 2 receptor mediates vascular smooth muscle cell apoptosis in cystic medial degeneration associated with Marfan’s syndrome. Circulation 2001 Sep 18; 104(12 Suppl. 1): 1282–7

    Google Scholar 

  23. Nagashima H, Uto K, Sakomura Y, et al. An angiotensin-converting enzyme inhibitor, not an angiotensin II type-1 receptor blocker, prevents beta-aminopropionitrile monofumarate-induced aortic dissection in rats. J Vasc Surg 2002 Oct; 36(4): 818–23

    PubMed  Google Scholar 

  24. Ahimastos AA, Aggarwal A, D’Orsa KM, et al. Effect of perindopril on large artery stiffness and aortic root diameter in patients with Marfan syndrome: a randomized controlled trial. JAMA 2007 Oct 3; 298(13): 1539–47

    Article  PubMed  CAS  Google Scholar 

  25. Habashi JP, Judge DP, Holm TM, et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science 2006 Apr 7; 312(5770): 117–21

    Article  PubMed  CAS  Google Scholar 

  26. Marsalese DL, Moodie DS, Vacante M, et al. Marfan’s syndrome: natural history and long-term follow-up of cardiovascular involvement. J Am Coll Cardiol 1989 Aug; 14(2): 422–8

    Article  PubMed  CAS  Google Scholar 

  27. Meijboom LJ, Westerhof BE, Nollen GJ, et al. Beta-blocking therapy in patients with the Marfan syndrome and entire aortic replacement. Eur J Cardiothorac Surg 2004 Nov; 26(5): 901–6

    Article  PubMed  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Prevent aortic complications in patients with Marfan’s syndrome by targeting the underlying histological and haemodynamic abnormalities. Drugs Ther. Perspect 24, 8–11 (2008). https://doi.org/10.2165/00042310-200824020-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-200824020-00003

Keywords

Search

Navigation